Relentless Pursuit Partners

Brenda Irwin is the Managing Partner and the public voice of the firm, authoring its monthly investor newsletter, the Relentless RoundUp, which often blends investment commentary with personal reflections on health and aging. The firm's website suggests a small, generalist team that includes Isabella Bertold, a competitive sailor who skippered Canada's inaugural Women's America's Cup campaign, indicating that investment decisions are likely centralized with Irwin. Beyond these two named professionals, no separate investment committee or external advisory board is disclosed.

The firm's sourcing model is heavily thesis-driven rather than purely network-referred, focusing on founders commercializing technologies that address chronic disease management, mobility, and healthy aging. Irwin's monthly RoundUp newsletter and LinkedIn activity reveal a personal network rooted in Canada's digital health and longevity communities, and portfolio company Aspect Biosystems originated at the University of British Columbia, suggesting active engagement with university spinout ecosystems in Vancouver. The firm does not publicly disclose a formal scout network or proprietary data platform for sourcing.

The portfolio page lists only direct startup investments and an 'angel portfolio' designation that includes Thrive Health, suggesting Relentless operates by making direct equity investments into companies rather than committing capital as a limited partner into other venture funds. No fund-of-funds activity is disclosed, and the language around portfolio construction — using terms like 'we invest in' — consistently points to direct venture deals.

Relentless targets early-stage companies, specifically at the seed and start-up phases, according to its investment strategy. Portfolio examples like Aspect Biosystems (founded at UBC) and VitaminLab (a Victoria-based personalized healthcare startup) are consistent with backing companies that have initial clinical or technical validation but are pre-commercialization or in early revenue. There is no evidence of growth-stage or later-stage involvement.

Relentless frames longevity as 'productive longevity,' meaning it invests explicitly in managing the progression of chronic diseases rather than only preventing them. The thesis accepts that 73% of people over 65 will live with at least one of the ten most common chronic conditions, so the portfolio includes devices like Orpyx Medical's pressure-sensing insoles for diabetic foot ulcers, not just wellness apps. The firm also treats exercise, music therapy, and personalized nutrition as clinical tools, evidenced by its investments in Lucid (music-based neurocognitive therapeutics) and VitaminLab.

The Relentless RoundUp serves as a direct channel for Managing Partner Brenda Irwin to articulate the firm's investment thesis through stories of personal health crises, family caregiving, and seasonal reflections on mental health, which reinforces the fund's brand as a values-driven health-tech investor. The 29th Edition, for example, cited her father's daily cycling routine as a proxy for the firm's mobility investment focus, turning a marketing tool into a narrative that aligns LPs with the fund's emotional and clinical logic. It also functions as a low-cost strategy to maintain visibility in Canada's niche health-tech startup community without paid marketing.